NCT07005713 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of BGB-16673 in Adults With Chronic Spontaneous Urticaria | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 19, 2025

Primary Completion Date

September 22, 2026

Study Completion Date

September 22, 2026

Conditions

Chronic Spontaneous Urticaria

Interventions

DRUG

BGB-16673

Administered orally

DRUG

Placebo

Administered orally

Trial Locations (10)

100000

RECRUITING

Peking University Third Hospital, Beijing

200443

NOT_YET_RECRUITING

Shanghai Skin Disease Hospital, Shanghai

310006

RECRUITING

Hangzhou First Peoples Hospital, Hangzhou

325000

RECRUITING

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou

410008

NOT_YET_RECRUITING

Xiangya Hospital of Central South University, Changsha

430022

RECRUITING

Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan

510515

NOT_YET_RECRUITING

Nanfang Hospital, Southern Medical University, Guangzhou

610021

NOT_YET_RECRUITING

Chengdu Second Peoples Hospital, Chengdu

630014

NOT_YET_RECRUITING

The First Affiliated Hospital of Chongqing Medical University, Chongqing

Unknown

RECRUITING

Dermatology Hospital of Southern Medical University, Guangzhou